Catalyst Pharmaceuticals (CPRX) Projected to Post Earnings on Wednesday

Catalyst Pharmaceuticals (NASDAQ:CPRX) is projected to announce its earnings results after the market closes on Wednesday, February 26th. Analysts expect the company to announce earnings of $0.32 per share and revenue of $134.20 million for the quarter. Investors interested in listening to the company’s conference call can do so using this link.

Catalyst Pharmaceuticals Price Performance

CPRX opened at $21.63 on Monday. Catalyst Pharmaceuticals has a fifty-two week low of $13.49 and a fifty-two week high of $24.64. The firm has a market capitalization of $2.58 billion, a P/E ratio of 18.33, a PEG ratio of 3.31 and a beta of 0.80. The company’s 50-day moving average is $22.25 and its 200 day moving average is $21.37.

Analyst Upgrades and Downgrades

Several research firms have commented on CPRX. Stephens began coverage on shares of Catalyst Pharmaceuticals in a research report on Monday, November 18th. They set an “overweight” rating and a $35.00 target price on the stock. Robert W. Baird assumed coverage on Catalyst Pharmaceuticals in a report on Tuesday, February 4th. They set an “outperform” rating and a $28.00 price target on the stock. Baird R W upgraded Catalyst Pharmaceuticals to a “strong-buy” rating in a research note on Monday, February 3rd. Bank of America reiterated a “buy” rating and set a $30.00 target price on shares of Catalyst Pharmaceuticals in a research note on Thursday, January 9th. Finally, StockNews.com lowered shares of Catalyst Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday, January 11th. Nine research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Catalyst Pharmaceuticals currently has an average rating of “Buy” and an average target price of $32.25.

Insider Activity at Catalyst Pharmaceuticals

In related news, insider Gary Ingenito sold 12,000 shares of the company’s stock in a transaction that occurred on Wednesday, November 27th. The shares were sold at an average price of $22.72, for a total transaction of $272,640.00. Following the sale, the insider now directly owns 51,391 shares in the company, valued at approximately $1,167,603.52. This represents a 18.93 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Steve Miller sold 50,000 shares of Catalyst Pharmaceuticals stock in a transaction that occurred on Tuesday, December 10th. The shares were sold at an average price of $21.93, for a total transaction of $1,096,500.00. Following the completion of the transaction, the insider now owns 686,996 shares of the company’s stock, valued at $15,065,822.28. This represents a 6.78 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 79,500 shares of company stock worth $1,754,140. Company insiders own 11.00% of the company’s stock.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.